The International Journal of Biological Markers (IJBM) has been focusing on circulating biomarkers in solid tumors since its foundation in 1986. In the last few years a substantial number of manuscripts on a multiplicity of novel biomarkers have been submitted to IJBM, whereas the interest in "traditional" tumor markers (TMs) such as CEA, CA15.3, etc. seems to decline, as if the clinical role of traditional TMs were clearly established. If this were true, then traditional TMs would be expected to be appropriately used. However, recent studies have shown that the number of ordered TMs is considerably higher than expected and TMs are frequently inappropriately requested (1, 2) . With approximately 13 million TM requests per year in Italy (1), serious consequences are predictable both for individual patients -high overdiagnosis rates -and the health care system -overload with unnecessary testing (3). In spite of the availability of clinical practice guidelines (CPGs), TM ordering rates have remained higher than expected over the years (1 ,2). Globally, it appears that health systems fail to optimally adopt evidence in circulating TM use (2).
